Challenges and advances in clinical applications of mesenchymal stromal cells.

Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, Lai P. · 2021

Read Challenges and advances in clinical applications of mesenchymal stromal cells. by Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, Lai P. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7880217.txt.

Introduction

Zhou and co-authors present a review of mesenchymal stromal cells and their use in medicine. These cells, also called mesenchymal stem cells, have been tested for many diseases. Trial results have often fallen short of the promise seen in animal work. The review asks why, and what can be done.

The authors discuss how loose identity criteria and natural variation make cell products hard to compare. They cover new lab methods and engineered materials that aim to make the cells more consistent. They also review attempts to use these cells against COVID-19. Readers get a clear map of the field's main hurdles. The review points to tighter standards and smarter cell design as the way forward.

Catalog record

CREATORZhou T, Yuan Z, Weng J, Pei D, Du X, He C, Lai P.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE112 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7880217

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Challenges and advances in clinical applications of mesenchymal stromal cells By Tian Zhou, Zenan Yuan, Jianyu Weng, Duanqing Pei, Xin Du, Chang He, Peilong Lai Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-021-01037-x ABSTRACT Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease. BACKGROUND Mesenchymal stromal cells (MSCs) are pluripotent non-hematopoietic stem cells with self-renewal capability [1] and being intensively investigated in clinical trials. Since the discovery of MSCs from bone marrow by Friedenstein in 1970s, MSCs have been isolated from various sources including muscle, umbilical cord, liver, placenta, skin, amniotic fluid, synovial membrane, and tooth root [2, 3], and tested in amounts of preclinical and clinical studies (Fig. 1). It is now understood that MSCs have wide-ranging physiological effects including the maintenance of tissue homeostasis and regeneration [4, 5], as well as the immunomodulatory activities suitable for therapeutic application [6]. So their indications have been expanded to graft-versus-host disease (GVHD), multiple sclerosis (MS), Crohn’s disease (CD), amyotrophic lateral sclerosis (ALS), myocardial infarction (MI), and acute respiratory distress syndrome (ARDS) [7–9].Fig.1Various sources of MSCs used in the registered clinical trials. MSCs isolated from bone marrow are most widely applied in clinical trials, followed by those from umbilical cord and adipose. MSCs from muscles, tooth are also used Over 300 clinical trials of MSC therapies have been completed in patients including but not limited to degenerative or autoimmune diseases (Table 1 lists some of the representative completed studies). Overall, MSCs have exhibited tolerable safety profile and demonstrated promising therapeutic benefits in some clinical settings, which led to regulatory approvals of MSCs in a few countries. In 2011, the Ministry of Food and Drug Safety (Korea FDA) approved Cartistem®, a MSC product derived from umbilical cord blood and developed by Medipost for the treatment of traumatic or degenerative osteoarthritis [10]. Thereafter, more MSC products including HeartiCellgram®, Mesoblast, TiGenix, and Stempeutics, were approved by regulatory authorities worldwide for the treatment of a variety of diseases. In the USA, Ryoncil (remestemcel-L) is promising to be the first FDA-approved GVHD treatment for children younger than 12, but is still in the stage of safety verification. The amount of clinics offering exogenous stem cell therapies has doubled from 2009 to 2014 in the USA. This boom in stem cell clinics with 351 companies putting stem cells for sale in 570 clinics in 2016 indicated the mal-practice of the MSC therapies [11]. Considering the fact that many of the applied exogenous stem cell therapies lack confirmation on safety and effectiveness from large-scale clinical trials and are even illegal, these medical mal-practices do threaten the development of MSC therapies [12].Table 1Some representative registered clinical trials of MSC therapiesNCT NumberTitlePhaseSponsor/CollaboratorsNCT02097641Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)Phase 2National Heart, Lung, and Blood Institute (NHLBI)Massachusetts General HospitalStanford UniversityUniversity of PittsburghUniversity of MinnesotaOhio State UniversityUniversity of California, San FranciscoNCT00957931Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCsPhase 2Stanford UniversityUniversity of MinnesotaUniversity of Alabama at BirminghamNCT01771913Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose-Derived Stem Cells (ADSC) Enriched Fat GraftsPhase 2University of Sao PauloNCT01909154Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia (CME-LEM1)Phase 1Puerta de Hierro University HospitalNCT03102879Encapsulated Mesenchymal Stem Cells for Dental Pulp RegenerationPhase 1Phase 2Universidad de los Andes, ChileCells for Cells, ChileNCT02467387A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart FailureN/ACardioCell LLCStemedica Cell Technologies, IncNCT02387749Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy PatientsN/ACairo UniversityNCT01932164Use of Mesenchymal Stem Cells for Alveolar Bone Tissue Engineering for Cleft Lip and Palate PatientsN/AHospital Sirio-LibanesNCT02481440Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCIPhase 1Phase 2Third Affiliated Hospital, Sun Yat-Sen University, ChinaNCT02165904Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCIPhase 1Emory UniversityNCT02330978Intravitreal Mesenchymal Stem Cell Transplantation in Advanced GlaucomaPhase 1University of Sao PauloNCT01183728NCT01586312Treatment of Knee Osteoarthritis With Autologous/ Allogenic Mesenchymal Stem CellsPhase 1Phase 2Red de Terapia CelularFundacion Teknon, Centro Medico Teknon, BarcelonaUniversity of ValladolidNCT02037204IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the KneePhase 1Phase 2UMC UtrechtNCT02958267Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the KneePhase 2OhioHealthNCT00587990Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)Phase 1Phase 2National Heart, Lung, and Blood Institute (NHLBI)Johns Hopkins University Specialized Center for Cell Based TherapyThe Emmes Company, LLCUniversity of MiamiNCT01385644A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary FibrosisPhase 1The Prince Charles HospitalMater Medical Research InstituteNCT02509156Stem Cell Injection in Cancer SurvivorsPhase 1The University of Texas Health Science Center, HoustonNational Heart, Lung, and Blood Institute (NHLBI)NCT02379442Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and CorticosteroidsPhase 1Phase 2National Heart, Lung, and Blood Institute (NHLBI)National Institutes of Health Clinical Center (CC)NCT01087996The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)Phase 1Phase 2University of MiamiNational Heart, Lung, and Blood Institute (NHLBI)The Emmes Company, LLCNCT02013674The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis Study (The TRIDENT Study)Phase 2The Emmes Company, LLCUniversity of MiamiNCT01392625PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)Phase 1Phase 2National Heart, Lung, and Blood Institute (NHLBI)University of MiamiNCT00768066The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)Phase 1Phase 2University of MiamiThe Emmes Company, LLCNCT00629018Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated CardiomyopathyPhase 2University Medical Centre LjubljanaBlood Transfusion Centre of SloveniaStanford UniversityNCT00927784Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVADPhase 2Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI)Angioblast SystemsN/A, not applicable In this review, we will focus on the major challenges of MSC therapies and the underlying factors leading to the failure of clinical trials. Recent advances and prospects concerning the translation of MSC techniques into clinical practices will also be discussed. CHALLENGES IN TECHNOLOGY TRANSFER OF MSCS FROM BENCH TO BEDSIDE Although transferring MSCs from bench to bedside is theoretically achievable, substantial failures have been reported in many early- or late-stage clinical trials, which account for the disapproval of many products by FDA [13]. Factors contributing to the failure of MSC clinical development include but not limited to the poor-quality control and inconsistent characteristics of MSCs in terms of immunocompatibility, stability, heterogeneity, differentiation, and migratory capacity [14, 15] (Fig. 2).Fig. 2The main challenges in clinical applications of MSCs. During preparation of the MSC products, the main challenges include: (1) heterogeneity of MSCs resulted from

Read the complete text